Adult-onset autoimmune diabetes encompasses a wide spectrum of heterogeneous genotypes and phenotypes, ranging from classic adult-onset type 1 diabetes mellitus to latent autoimmune diabetes in adults (LADA)
The heterogeneity of LADA arises from its definition as being present in any adult with diabetes who does not require insulin and who is positive for any islet autoantibody, regardless of titre, number or epitope specificity
The heterogeneity of LADA manifests in different clinical phenotypes, ranging from prevalent insulin resistance to prevalent insulin deficiency, each of which might be associated with different autoimmune and metabolic markers
Although patients with LADA are leaner and have healthier lipid and blood pressure profiles, evidence shows that there is no difference in cardiovascular outcomes between these patients and those with type 2 diabetes mellitus
The extensive heterogeneity of adult-onset autoimmune diabetes, and particularly LADA, makes it difficult to determine an a priori algorithm for treatment
The successful treatment of adult-onset autoimmune diabetes will require a personalized medicine approach that takes into account the intrinsic characteristics of each patient
Adult-onset autoimmune diabetes is a heterogeneous disease that is characterized by a reduced genetic load, a less intensive autoimmune process and a mild metabolic decompensation at onset compared with young-onset type 1 diabetes mellitus (T1DM). The majority of patients with adult-onset autoimmune diabetes do not require insulin treatment for at least 6 months after diagnosis. Such patients are defined as having latent autoimmune diabetes in adults (LADA), which is distinct from classic adult-onset T1DM. The extensive heterogeneity of adult-onset autoimmune diabetes is apparent beyond the distinction between classic adult-onset T1DM and LADA. LADA is characterized by genetic, phenotypic and humoral heterogeneity, encompassing different degrees of insulin resistance and autoimmunity; this heterogeneity is probably a result of different pathological mechanisms, which have implications for treatment. The existence of heterogeneous phenotypes in LADA makes it difficult to establish an a priori treatment algorithm, and therefore, a personalized medicine approach is required. In this Review, we discuss the current understanding and gaps in knowledge regarding the pathophysiology and clinical features of adult-onset autoimmune diabetes and highlight the similarities and differences with classic T1DM and type 2 diabetes mellitus.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Interaction between plasma phospholipid odd-chain fatty acids and GAD65 autoantibodies on the incidence of adult-onset diabetes: the EPIC-InterAct case–cohort study
Diabetologia Open Access 10 June 2023
L’eterogeneità del meccanismo autoimmune che conduce al diabete tipo 1 giustifica il fallimento dell’immunoterapia?
L'Endocrinologo Open Access 11 May 2023
Diabetology & Metabolic Syndrome Open Access 03 May 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Mølbak, A. G., Christau, B., Marner, B., Borch-Johnsen, K. & Nerup, J. Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet. Med. 11, 650–655 (1994).
Sabbah, E. et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 23, 1326–1332 (2000).
Howson, J. M. et al. Genetic analysis of adult-onset autoimmune diabetes. Diabetes 60, 2645–2653 (2011).
Hernandez, M. et al. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9. BMC Endocr. Disord. 15, 1 (2015).
Tuomi, T. et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42, 359–362 (1993).
Hawa, M. I. et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care 36, 908–913 (2013).
Maddaloni, E. et al. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS ONE 10, e0131837 (2015).
Zimmet, P. Z. et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet. Med. 11, 299–303 (1994).
Juneja, R. & Palmer, J. P. Type 1 1/2 diabetes: myth or reality? Autoimmunity 29, 65–83 (1999).
Pozzilli, P. & Di Mario, U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 24, 1460–1467 (2001).
Kobayashi, T. et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann. NY Acad. Sci. 958, 117–130 (2001).
Fourlanos, S. et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48, 2206–2212 (2005).
Brophy, S. et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 31, 439–441 (2008).
American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 40 (Suppl. 1), S11–S24 (2017).
Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15, 539–553 (1998).
Bruno, G. et al. Incidence of type 1 and type 2 diabetes in adults aged 30–49 years: the population-based registry in the province of Turin, Italy. Diabetes Care 28, 2613–2619 (2005).
Rawshani, A. et al. The incidence of diabetes among 0–34 year olds in Sweden: new data and better methods. Diabetologia 57, 1375–1381 (2014).
Turner, R. et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350, 1288–1293 (1997).
Tuomi, T. et al. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48, 150–157 (1999).
Takeda, H. et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 25, 995–1001 (2002).
Zinman, B. et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 53, 3193–3200 (2004).
Buzzetti, R. et al. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 30, 932–938 (2007).
Radtke, M. A., Midthjell, K., Nilsen, T. I. & Grill, V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trondelag Health (HUNT) study. Diabetes Care 32, 245–250 (2009).
Qi, X. et al. Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study. Diabetes Care 34, 66–70 (2011).
Maioli, M. et al. Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults. Eur. J. Endocrinol. 163, 541–549 (2010).
Zhou, Z. et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China Study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62, 543–550 (2013).
Tuomi, T. et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383, 1084–1094 (2014).
Laugesen, E., Østergaard, J. A. & Leslie, R. D. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Danish Diabetes Academy Workshop and Workshop Speakers. Diabet. Med. 32, 843–852 (2015).
Lampasona, V. et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: non insulin requiring autoimmune diabetes (NIRAD) 4. Diabetes Care 33, 104–108 (2010).
Yang, Z. et al. Childhood diabetes in China. Enormous variation by place and ethnic group. Diabetes Care 21, 525–529 (1998).
Sutanegara, D. & Budhiarta, A. A. The epidemiology and management of diabetes mellitus in Indonesia. Diabetes Res. Clin. Pract. 50, S9–S16 (2000).
Mohatt, J., Gilliam, L. K., Bekris, L., Ebbesson, S. & Lernmark, A. Type 1 diabetes-related autoantibodies are rare in Alaska native populations. Int. J. Circumpolar Health 61, 21–31 (2002).
Dowse, G. K. et al. Lack of antibodies to glutamic acid decarboxylase in young adults of the high diabetes prevalence Wanigela people of Papua New Guinea. Diabetes Res. Clin. Pract. 24, 195–198 (1994).
Barinas-Mitchell, E. et al. Islet cell autoimmunity in a triethnic adult population of the Third National Health and Nutrition Examination Survey. Diabetes 53, 1293–1302 (2004).
Temneanu, O. R., Trandafir, L. M. & Purcarea, M. R. Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J. Med. Life 3, 235–239 (2016).
Leslie, R. D., Palmer, J., Schloot, N. C. & Lernmark, A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 59, 13–20 (2016).
Nisticò, L. et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum. Mol. Genet. 5, 1075–1080 (1996).
Bottini, N. et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36, 337–338 (2004).
Grant, S. F. et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38, 320–323 (2006).
Frayling, T. M. et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889–894 (2007).
Atkinson, M. A. & Eisenbarth, G. S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358, 221–229 (2001).
Leslie, R. D. & Delli Castelli, M. Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 53, 3033–3040 (2004).
Caillat-Zucman, S. et al. Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J. Clin. Invest. 90, 2242–2250 (1992).
Petrone, A. et al. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab. Res. Rev. 21, 271–275 (2005).
Andersen, M. K. et al. Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years. Diabetes Care 33, 2062–2064 (2010).
Van der Auwera, B. J. et al. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. The Belgian Diabetes Registry. Clin. Exp. Immunol. 110, 98–103 (1997).
Cosentino, A., Gambelunghe, G., Tortoioli, C. & Falorni, A. CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults. Ann. NY Acad. Sci. 958, 337–340 (2002).
Bennett, S. T. et al. Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. Nat. Genet. 17, 350–352 (1997).
Haller, K. et al. Insulin gene VNTR, CTLA-4 + 49A/G and HLA-DQB1 alleles distinguish latent autoimmune diabetes in adults from type 1 diabetes and from type 2 diabetes group. Tissue Antigens 69, 21–27 (2007).
Gambelunghe, G. Two distinct MICA gene markers discriminate major autoimmune diabetes types. J. Clin. Endocrinol. Metab. 86, 3754–3760 (2001).
Sanjeevi, C. B. Genetics of latent autoimmune diabetes in adults. Ann. NY Acad. Sci. 958, 107–111 (2002).
Brooks-Worrell, B. M., Juneja, R., Minokadeh, A., Greenbaum, C. J. & Palmer, J. P. Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patents. Diabetes 48, 983–988 (1999).
Signore, A. et al. Detection of insulitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10). Diabetes Care 38, 652–658 (2015).
Brooks-Worrell, B. M., Reichow, J. L., Goel, A., Ismail, H. & Palmer, J. P. Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 34, 168–173 (2011).
Graham, J. et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 51, 1346–1355 (2002).
Kawasaki, E. Type 1 diabetes and autoimmunity. Clin. Pediatr. Endocrinol. 23, 99–105 (2014).
Tiberti, C. et al. Identification of tyrosine phosphatase 2(256–760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes 57, 1276–1283 (2008).
Buzzetti, R. et al. Tyrosine phosphatase-related islet antigen 2(256–760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. Diabetes Care 38, 513–520 (2015).
Pham, M. N. et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: action LADA 4. Diabetologia 54, 1630–1638 (2011).
Ferrannini, E. The stunned beta cell: a brief history. Cell Metab. 11, 349–352 (2010).
Stenström, G., Gottsäter, A., Bakhtadze, E., Berger, B. & Sundkvist, G. Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment. Diabetes 54 (Suppl. 2), S68–S72 (2005).
Barker, A. et al. Age-dependent decline of β-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes. Metab. 16, 262–267 (2014).
Joanes, D. N. & Gill, C. A. Comparing measures of sample skewness and kurtosis. Statistician 47, 183–189 (1998).
Petrone, A. et al. The protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3. Diabetes Care 31, 534–538 (2008).
Zampetti, S. et al. Association of TCF7L2 gene variants with low GAD autoantibody titre in LADA subjects (NIRAD Study 5). Diabet. Med. 27, 701–704 (2010).
Pettersen, E., Skorpen, F., Kvaløy, K., Midthjell, K. & Grill, V. Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the Nord-Trøndelag Health Study. Diabetes 59, 302–310 (2010).
Zampetti, S. et al. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). J. Clin. Endocrinol. Metab. 97, 3759–3765 (2012).
Bottazzo, G. F. et al. IA-2 antibody prevalence and risk assessment of early insulin requirementin subjects presenting with type 2diabetes (UKPDS 71). Diabetologia 48, 703–708 (2005).
Genovese, S. et al. Clinical phenotype and β-cell autoimmunity in Italian patients with adult-onset diabetes. Eur. J. Endocrinol. 154, 441–447 (2006).
Desai, M. et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 50, 2052–2060 (2007).
Zampetti, S. et al.High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). Eur. J. Endocrinol. 171, 697–704 (2014).
Itariu, B. K. & Stulnig, T. M. Autoimmune aspects of type 2 diabetes mellitus — a mini-review. Gerontology 60, 189–196 (2014).
Zhang, B., Lan, M. S. & Notkins, A. L. Autoantibodies to IA-2 in IDDM: location of major antigenic determinants. Diabetes 46, 40–43 (1997).
Brooks-Worrell, B., Narla, R. & Palmer, J. P. Islet autoimmunity in phenotypic type 2 diabetes patients. Diabetes Obes. Metab. 3, 137–140 (2013).
Palmer, J. P., Hampe, C. S., Chiu, H., Goel, A. & Brooks-Worrell, B. M. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 54, S62–S67 (2005).
Acevedo-Calado, M. et al. Identification of unique antigenic determinants in the amino terminus of IA-2 (ICA512) in childhood and adult autoimmune diabetes: new biomarker development. Diabetes Care 40, 561–568 (2017).
Andersen, M. K. et al. Type 2 diabetes susceptibility gene variants predispose to adult-onset autoimmune diabetes. Diabetologia 57, 1859–1868 (2014).
Carlsson, A., Sundkvist, G., Groop, L. & Tuomi, T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J. Clin. Endocrinol. Metab. 85, 76–80 (2000).
Maruyama, T. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann. NY Acad. Sci. 1005, 362–369 (2003).
Fourlanos, S. et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 29, 970–975 (2006).
Gregg, E. W. et al. Changes in diabetes-related complications in the United States1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014).
Lind, M. et al. Glycemic control and excess mortality in type 1 diabetes. N. Engl. J. Med. 371, 1972–1982 (2014).
Secrest, A. M., Becker, D. J., Kelsey, S. F., Laporte, R. E. & Orchard, T. J. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes 59, 3216–3222 (2010).
Myhill, P. et al. Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. Diabet. Med. 25, 1245–1250 (2008).
Isomaa, B. et al. Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). Diabetes Care 22, 1347–1353 (1999).
Lu, J. et al. Associations between clinical characteristics and chronic complications in latent autoimmune diabetes in adults and type 2 diabetes. Diabetes. Metab. Res. Rev. 31, 411–420 (2015).
Wang, C. et al. Evaluating peripheral nerve function in asymptomatic patients with type 2 diabetes or latent autoimmune diabetes of adults (LADA): results from nerve conduction studies. J. Diabetes Complications 29, 265–269 (2015).
Hawa, M. I. et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care 37, 1643–1649 (2014).
Arikan, E., Sabuncu, T., Ozer, E. M. & Hatemi, H. The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with Type 2 diabetes mellitus. J. Diabetes Complications 19, 254–258 (2005).
Balme, M., McAllister, I., Davis, W. A. & Davis, T. M. E. Retinopathy in latent autoimmune diabetes of adults: the Fremantle Diabetes Study. Diabet. Med. 19, 602–605 (2002).
Harris, M. I., Klein, R., Welborn, T. A. & Knuiman, M. W. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 15, 815–819 (1992).
Porta, M. et al. Estimating the delay between onset and diagnosis of type 2 diabetesfrom the time course of retinopathy prevalence. Diabetes Care 37, 1668–1674 (2014).
Martinell, M. et al. Prevalence and risk factors for diabetic retinopathy at diagnosis (DRAD) in patients recently diagnosed with type 2 diabetes (T2D) or latent autoimmune diabetes in the adult (LADA). J. Diabetes Complications 30, 1456–1461 (2016).
Roh, M.-O., Jung, C.-H., Kim, B.-Y., Mok, J.-O. & Kim, C.-H. The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. Acta Diabetol. 50, 129–134 (2013).
Baum, P. et al. Diabetic neuropathy in patients with latent autoimmune diabetes of the adult (LADA) compared with patients with type 1 and type 2 diabetes. J. Neurol. 250, 682–687 (2003).
Olsson, L. et al. Mortality in adult-onset autoimmune diabetes is associated with poor glycemic control: results from the HUNT Study. Diabetes Care 36, 3971–3978 (2013).
Brophy, S., Davies, H., Mannan, S., Brunt, H. & Williams, R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst. Rev. 9, CD006165 (2011).
Kobayashi, T., Nakanishi, K., Murase, T. & Kosaka, K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 45, 622–626 (1996).
Maruyama, T. et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J. Clin. Endocrinol. Metab. 93, 2115–2121 (2008).
Thunander, M., Thorgeirsson, H., Törn, C., Petersson, C. & Landin-Olsson, M. β-Cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur. J. Endocrinol. 164, 239–245 (2011).
Zhu, L., Liu, Y., Huang, M., Wei, H. & Liu, Z. Study on improvement of islet beta cell function in patients with latent autoimmune diabetes mellitus in adults by integrative Chinese and Western medicine [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi 24, 581–584 (2004).
Davis, T. M. E. et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 48, 695–702 (2005).
American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care 38, S41–S48 (2015).
Cernea, S., Buzzetti, R. & Pozzilli, P. β-Cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 32, S246–S252 (2009).
Pozzilli, P., Maddaloni, E. & Buzzetti, R. Combination immunotherapies for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 11, 289–297 (2015).
Rosário, P. W. S. et al. Latent autoimmune diabetes in adults (LADA): usefulness ofanti-GAD antibody titers and benefit of early insulinization. Arq. Bras. Endocrinol. Metabol. 51, 52–58 (2007).
Steffes, M. W., Sibley, S., Jackson, M. & Thomas, W. Beta-cell function and thedevelopment of diabetes-related complications in the diabetes control and complicationstrial. Diabetes Care 26, 832–836 (2003).
Agardh, C.-D. et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Compl. 19, 238–246 (2005).
Pozzilli, P. & Guglielmi, C. Immunomodulation for the prevention of SPIDDM and LADA. Ann. NY Acad. Sci. 1079, 90–98 (2006).
Agardh, C. D., Lynch, K. F., Palmér, M., Link, K. & Lernmark, A. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 52, 1363–1368 (2009).
Pettus, J., Hirsch, I. & Edelman, S. GLP-1 agonists in type 1 diabetes. Clin. Immunol. 149, 317–323 (2013).
Farilla, L. et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144, 5149–5158 (2003).
Jones, A. G. et al. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 39, 250–257 (2016).
Johansen, O. E. et al. C-Peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care 37, e11–e12 (2014).
Zhao, Y. et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J. Clin. Endocrinol. Metab. 99, E876–E880 (2014).
Buzzetti, R., Pozzilli, P., Frederich, R., Iqbal, N. & Hirshberg, B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab. Res. Rev. 32, 289–296 (2016).
Carlsson, S., Midthjell, K., Grill, V. & Nord-Trøndelag study. Smoking is associated with an increased risk of type 2 diabetes but a decreased risk of autoimmune diabetes in adults: an 11-year follow-up of incidence of diabetes in the Nord-Trøndelag study. Diabetologia 47, 1953–1956 (2004).
Rasouli, B. et al. Smoking is associated with reduced risk of autoimmune diabetes in adults contrasting with increased risk in overweight men with type 2 diabetes: a 22-year follow-up of the HUNT study. Diabetes Care 36, 604–610 (2013).
Rasouli, B. Smoking and the Risk of LADA: results from a Swedish population-based case-control study. Diabetes Care 39, 794–800 (2016).
Rasouli, B. Alcohol and the risk for latent autoimmune diabetes in adults: results based on Swedish ESTRID study. Eur. J. Endocrinol. 171, 535–543 (2014).
Zhou, Z. et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 21, 203–208 (2005).
Argoud, G. M., Schade, D. S. & Eaton, R. P. Insulin suppresses its own secretion in vivo. Diabetes 36, 959–962 (1987).
Maddaloni, E. & Pozzilli, P. SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes). Endocrine 46, 3–5 (2014).
Biesenbach, G., Auinger, M., Clodi, M., Prischl, F. & Kramar, R. Prevalence of LADA and frequency of GAD antibodies in diabetic patients with end-stage renal disease and dialysis treatment in Austria. Nephrol. Dial. Transplant. 20, 559–565 (2005).
The Non Insulin Requiring Autoimmune Diabetes Study was sponsored by 'Fondazione Diabete e Ricerca' of the Italian Society of Diabetology.
The authors declare no competing financial interests.
About this article
Cite this article
Buzzetti, R., Zampetti, S. & Maddaloni, E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol 13, 674–686 (2017). https://doi.org/10.1038/nrendo.2017.99